The haematocrit and platelet target in polycythemia vera
about
Guidelines for the management of myeloproliferative neoplasmsPolycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617FAnnual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.A review of the reporting and handling of missing data in cohort studies with repeated assessment of exposure measures.Surgery for lung adenocarcinoma with smokers' polycythemia: a case report.How I treat essential thrombocythemia.The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera.Cerebral infarction due to smoker's polycythemia.Mechanisms of thrombogenesis in polycythemia veraThrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera?Current applications of therapeutic phlebotomy.Experimental therapeutics for patients with myeloproliferative neoplasias.Treatment options for essential thrombocythemia and polycythemia vera.Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.New JAK2 inhibitors for myeloproliferative neoplasms.Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.Polycythemia vera: current pharmacotherapy and future directions.Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management.High hematocrit resulting from administration of erythropoiesis-stimulating agents is not fully predictive of mortality or toxicities in preclinical species.Target hematologic values in the management of essential thrombocythemia and polycythemia vera.Therapeutic apheresis for patients with cancer.Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia.Diagnosis and management of congenital and idiopathic erythrocytosis.Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study.Prevalence of venous thromboembolism in patients with secondary polycythemia.High hematocrit as a risk factor for venous thrombosis. Cause or innocent bystander?Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status.Aspirin dose increase from 75 to 150 mg suppresses red blood cell contribution to suboptimal platelet response to aspirin in patients with CAD.Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.Polycythemia vera treatment algorithm 2018.Red blood cells in thrombosis.Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
P2860
Q26778326-39DCC1B2-DF78-4C8C-AB30-5CF6C2713F49Q26795666-F510D1D5-CD67-41BF-956F-07EA2DFED598Q34166859-7335273A-2E9E-49C4-8879-DA5419068B7FQ34302770-307DD61E-6A32-4EC7-A05A-D5C99F8C4FD3Q34333257-04F611DF-72B4-49E3-89D4-5996BA2A92FCQ34572381-17286A4D-975F-47A2-8138-A9D0B8AF5DA2Q35132271-09559818-F057-44CA-98E9-D7520A1EABFCQ35433005-93AF30E9-803D-406C-AA0F-CF500EEA03C7Q35519844-C1F8F286-3646-4748-9C29-9252EC619E22Q35738656-5995F8D0-CD65-4604-9A24-F92717BC1276Q36941052-AFF2F134-BA60-4C1A-9D93-C09EABAF641AQ37229486-EE8663D5-4F37-4908-A3D1-E642FDEDAE2FQ37602391-DA03F59F-986D-47E5-96F4-E620DDFC2BE4Q37797983-C33793AF-7F0C-49EA-8D2A-92262668AE7AQ37810107-B1015E7D-F390-4688-8540-26629F74AE49Q37833893-3CC8AD67-D31A-4EC8-AC1F-722DCEC6927BQ37869152-748130FE-F173-43CE-8E01-745788E422D8Q37877727-C949B275-2B0C-4DB4-A3AE-A37FC590622AQ37983791-BEF4E102-5AC4-4079-80F7-2320D3CF1DA7Q38014534-1969CAD2-6640-4343-A749-5CDAF8E261F2Q38088262-A0AB4F20-3088-4DCC-8598-76B6233832AEQ38100371-920FEE7F-CBF0-4F4B-879F-DEA789626DE8Q38106921-FC382824-7049-416B-BC7C-954FCC156435Q38210664-2C59EED8-2506-40C2-869D-32F4A1783E68Q38287610-981CAED7-374D-4668-BE6F-4AB393E57654Q38341625-EA74ECDB-F28B-48E6-B478-AF76095A417AQ39059693-AA7111A4-9406-401F-8077-1B2A6BB21AF1Q39869449-C35316C7-2B1D-48AB-98D5-B05D04CEEFB6Q40555261-FF1AD31A-41F1-41E4-ABB8-93F6EE6EF71FQ42130186-D8AADAD1-5ABE-463C-96EF-C8ED0DF679C2Q42922568-538E2F9F-B431-4436-A72C-105573D3F291Q44236518-5D8EFC8D-23BE-4499-BCF0-20FCF2E23AA2Q46437192-3FA411CA-7D9A-4261-89C8-74DBFAA5DEBEQ46636672-65D2ADA1-1F77-4861-BC2A-CA5841A44408Q47565670-63A937EF-1E5E-4DD8-ADF5-F58C64540A2BQ48003288-BACA767F-9939-45DA-BCEF-E758531A0B4AQ54573577-664F348C-F4AA-425D-87FB-FD8C584BC887
P2860
The haematocrit and platelet target in polycythemia vera
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The haematocrit and platelet target in polycythemia vera
@ast
The haematocrit and platelet target in polycythemia vera
@en
The haematocrit and platelet target in polycythemia vera
@nl
type
label
The haematocrit and platelet target in polycythemia vera
@ast
The haematocrit and platelet target in polycythemia vera
@en
The haematocrit and platelet target in polycythemia vera
@nl
prefLabel
The haematocrit and platelet target in polycythemia vera
@ast
The haematocrit and platelet target in polycythemia vera
@en
The haematocrit and platelet target in polycythemia vera
@nl
P2093
P2860
P50
P1476
The haematocrit and platelet target in polycythemia vera
@en
P2093
Alessandro M Vannucchi
Anne W S Rutjes
Giovanna Borrelli
Giuseppe Leone
Guido Finazzi
Marco Ruggeri
Roberto Marchioli
Tiziano Barbui
P2860
P304
P356
10.1111/J.1365-2141.2006.06430.X
P407
P50
P577
2007-01-01T00:00:00Z